Alternatives to specific uric acid lowering treatment in gout in patients with cardiovascular disease

BMJ. 2018 Sep 20:362:k3895. doi: 10.1136/bmj.k3895.
No abstract available

Publication types

  • Letter

MeSH terms

  • Amlodipine / adverse effects
  • Amlodipine / therapeutic use
  • Angiotensin II Type 1 Receptor Blockers / adverse effects
  • Atorvastatin / administration & dosage
  • Atorvastatin / adverse effects
  • Atorvastatin / therapeutic use
  • Calcium Channel Blockers / adverse effects
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / epidemiology
  • Clopidogrel / adverse effects
  • Clopidogrel / therapeutic use
  • Gout / drug therapy*
  • Gout / epidemiology
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
  • Losartan / adverse effects
  • Losartan / therapeutic use
  • Purinergic P2Y Receptor Antagonists / adverse effects
  • Risk Factors
  • Uric Acid / antagonists & inhibitors*
  • Uric Acid / blood

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Calcium Channel Blockers
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Purinergic P2Y Receptor Antagonists
  • Amlodipine
  • Uric Acid
  • Atorvastatin
  • Clopidogrel
  • Losartan